文献速递其他结缔组织病

抗Ro52自身抗体与幼年型肌炎患者间质性肺病及更严重疾病相关

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.
PubMed 文献 · Ann Rheum Dis · 2019-04-24

该研究在302例幼年皮肌炎、25例幼年多发性肌炎和44例幼年结缔组织病-肌炎重叠患者中检测抗Ro52自身抗体,发现其阳性率分别为14%、12%和18%。抗Ro52抗体与抗氨酰tRNA合成酶抗体(64%)和抗MDA5抗体(31%)相关,且独立于肌炎特异性抗体与间质性肺病相关(36% vs 4%)。抗Ro52阳性患者病程更易慢性化、缓解更少、用药更多。

要点

  • 抗Ro52抗体在幼年型肌炎中阳性率约14%,与抗合成酶抗体和抗MDA5抗体强相关。
  • 控制肌炎特异性抗体后,抗Ro52抗体仍与间质性肺病显著相关(36% vs 4%)。
  • 抗Ro52阳性患者病程更慢性、缓解率更低且用药种类更多。

核心结论

  • 抗Ro52自身抗体在幼年型肌炎患者中与间质性肺病及更严重疾病和较差预后相关。

研究设计与样本

  • 研究纳入302例幼年皮肌炎、25例幼年多发性肌炎和44例幼年结缔组织病-肌炎重叠患者,采用ELISA法筛查血清抗Ro52自身抗体并比较临床特征。

主要发现

  • 抗Ro52抗体在幼年皮肌炎中阳性率为14%,幼年多发性肌炎为12%,幼年结缔组织病-肌炎重叠为18%。
  • 抗Ro52抗体在抗氨酰tRNA合成酶抗体阳性患者中更常见(64%,p<0.001),在抗MDA5抗体阳性患者中也更常见(31%,p<0.05)。
  • 控制肌炎特异性自身抗体后,抗Ro52抗体与间质性肺病存在关联(36% vs 4%,p<0.001)。
  • 抗Ro52阳性患者病程更常呈慢性、缓解较少且接受的药物种类更多。

临床怎么用

  • 对幼年型肌炎患者检测抗Ro52抗体有助于识别间质性肺病高风险及可能更严重病程的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis. METHODS: We screened sera from 302 patients with juvenile dermatomyositis (JDM), 25 patients with juvenile polymyositis (JPM) and 44 patients with juvenile connective tissue disease-myositis overlap (JCTM) for anti-Ro52 autoantibodies by ELISA. Clinical characteristics were compared between myositis patients with and without anti-Ro52 autoantibodies. RESULTS: Anti-Ro52 autoantibodies were found in 14% patients with JDM, 12% with JPM and 18% with JCTM. Anti-Ro52 autoantibodies were more frequent in patients with antiaminoacyl tRNA synthetase (64%, p<0.001) and anti-MDA5 (31%, p<0.05) autoantibodies. After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001). Disease course was more frequently chronic, remission was less common, and an increased number of medications was received in anti-Ro52 positive patients. CONCLUSIONS: Anti-Ro52 autoantibodies are present in 14% of patients with juvenile myositis and are strongly associated with anti-MDA5 and antiaminoacyl tRNA synthetase autoantibodies. In all patients with juvenile myositis, those with anti-Ro52 autoantibodies were more likely to have ILD. Furthermore, patients with anti-Ro52 autoantibodies have more severe disease and a poorer prognosis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Sabbagh S, Pinal-Fernandez I, Kishi T, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis. 2019. PMID: 31018961. doi:10.1136/annrheumdis-2018-215004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。